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The TGFb/activin signaling pathway is important for the maintenance of human embryonic stem cells. In this
issue of Cell Stem Cell, Xu et al. (2008) show that this pathway upregulates the expression of a key pluripo-
tency gene NANOG through SMAD2/3.Pluripotent embryonic stem cells (ESCs)
have been derived from the blastocysts
of various mammals, and they can be
propagated in vitro under conditions that
promote self-renewal (Rossant, 2008). A
distinctive difference between human
and mouse ESCs is the requirement for
different growth factors during the in vitro
culture of these cells. Work performed
over the past decade has defined the
growth factors necessary to propagate
ESCs in the absence of serum or feeder
cells (Rao and Zandstra, 2005). Mouse
ESCs remain undifferentiated in the pres-
ence of leukemia inhibitory factor (LIF)
and bone morphogenetic protein (BMP)
(Ying et al., 2003). The LIF and BMP path-
ways activate Stat3 and Smad1, respec-
tively (Ying et al., 2003; Boiani and
Scho¨ler, 2005). In contrast, the propaga-
tion of human ESCs does not require
LIF, and BMPs promote trophectoderm
differentiation. Instead, most feeder-free
culture conditions for human ESCs re-
quire the supplement of basic fibroblast
growth factor (bFGF) and transforming
growth factor b (TGFb)/activin (Rao and
Zandstra, 2005). Hence, there is tremen-
dous interest in understanding how the
various types of pluripotent stem cells
make use of different growth factors that
operate through seemingly diverse signal-
ing pathways to maintain the self-renew-
ing state.
The TGFb/activin signaling is transmit-
ted by the phosphorylation of SMAD2/3,
which is abundant in undifferentiated
human ESCs. Inhibition of TGFb/activin
receptors by the chemical inhibitor
SB431542 reduces SMAD2/3 phosphory-
lation and induces differentiation. The tar-
get genes of SMAD2/3 and the roles they
play in ESC self-renewal are not known.Both mouse and human ESCs specifically
upregulate a set of common transcription
factors, such as Oct4, Sox2, and Nanog,
which constitute the ‘‘core’’ intrinsic fac-
tors that are required to sustain the self-
renewing and pluripotent cellular state
(Boiani and Scho¨ler, 2005). In this issue,
Thomson and colleagues show that
SMAD2/3 bind directly to the NANOG
proximal promoter in human ESCs (Xu
et al., 2008). Mutations introduced to
the SMAD-binding elements reduced
NANOG proximal promoter activity, indi-
cating that the SMAD binding sites are
important cis-regulatory elements. Fur-
thermore, the NANOG promoter activity
is less active when human ESCs are
treated with the SB431542 inhibitor or
upon TGFb1 withdrawal. This study also
sets the stage for addressing some inter-
esting questions. What are the other tar-
get genes of SMAD2/3 in human ESCs?
Besides SMAD2/3, what other transcrip-
tion factors are controlled by the TGFb/
activin pathway?
Strikingly, the authors also show that
overexpression of NANOG can bypass
the requirement for TGFb/activin and
bFGF. This finding strongly suggests
that the two signaling pathways promote
pluripotency of human ESCs through the
sustained expression of NANOG. This re-
sult raises the possibility that the FGF
pathway may also directly regulate pluri-
potency genes such as NANOG. Overall,
this interesting study provides the first
key evidence that the TGFb/activin signal-
ing cascade activates a critical pluripo-
tency gene in human ESCs via SMAD2/3
(Figure 1A).
Unlike SMAD2/3, BMP-responsive
SMADs such as SMAD1, SMAD5, and
SMAD8 appear to have a repressive roleCell Stem Cfor the expression of pluripotency-associ-
ated genes in human ESCs. Xu et al. also
demonstrate that SMAD1 binds to the
NANOG promoter (Xu et al., 2008).
BMP4 treatment, which induces trophec-
toderm differentiation, leads to increased
SMAD1 occupancy. Although it is not
clear if SMAD2/3 compete with SMAD1/
5/8 for the Smad-binding elements at
theNANOG promoter, the result suggests
that an intricate balance of SMAD2/3 and
SMAD1/5/8 could modulate the expres-
sion of NANOG and potentially determine
the choice between undifferentiated and
lineage-committed fates. The findings of
Xu et al. also underscore the potential im-
pact of slight variances in the culture con-
ditions used to maintain human ESCs in
different settings. That is, as the specific
combination and concentration of growth
factors present in human ESC cultures is
likely to impact directly on the expression
of pluripotency gene(s), comparisons of
the proliferative or pluripotent state of
these cells between protocols may not
be accurate or reliable.
The BMP/Smad1 pathway appears to
function differently in mouse ESCs.
Smad1 has been shown to interact with
Nanog and bind to the Nanog enhancer
element in a BMP4-dependent manner
(Suzuki et al., 2006; Chen et al., 2008;
Figure 1B). Genome-wide mapping of
Smad1- and Nanog-binding locations
reveal that the two transcriptional regula-
tory circuitries are integrated through ex-
tensive co-occupancy across the entire
genome (Chen et al., 2008). Hence, it will
be of interest to examine if human
NANOG interacts with SMAD2/3 or
SMAD1/5/8 (Figure 1A) and whether
NANOG-binding loci overlap substantially
with the SMADs in human ESCs. If suchell 3, August 7, 2008 ª2008 Elsevier Inc. 127
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Previewsa biochemical link is found, then it will
further connect NANOG to the SMAD
Figure 1. Extrinsic Signals Regulate
Intrinsic Pluripotency Genes in
Embryo-Derived Stem Cells
(A) The TGFb/activin signaling pathway activates
the NANOG gene via SMAD2/3, while BMP signals
suppress NANOG through SMAD1/5/8 in human
ESCs. Gray arrows indicate potential interactions.
Red circles represent SMAD binding elements.
(B) BMP4 signaling activates the Nanog gene
through Smad1 activation, which is known to inter-
act with Nanog protein in mouse ESCs. The green
circle represents Nanog and Smad1 cobound site.
(C) The TGFb/activin-Smad2/3 or BMP-Smad1/5/8
signaling pathways may regulate the Nanog gene
in mouse epiblast stem cells. The genes (printed
in italics) are represented by rectangles, transcrip-
tion factors are represented by ovals, and growth
factors are represented by diamond boxes.128 Cell Stem Cell 3, August 7, 2008 ª2008pathway in a manner that has been de-
scribed in mouse ESCs. Although signal-
modulated transcriptional regulation is
important to mediate rapid control over
the expression of Nanog, a recent study
uncovered a novel mode of regulating
Nanog at the posttranslational level (Fujita
et al., 2008). Zwaka and colleagues show
that Caspase-3 is involved in cleaving
Nanog, which provides an efficient way
to destroy the gene product controlling
pluripotency. This pathway may allow
ESCs to respond rapidly to disassemble
the pluripotency regulatory network
upon differentiation.
Pluripotent mouse cell lines that are ca-
pable of expansion in human ESC media
(containing FGF2 and activin or a serum
replacement supplement) have been
derived from the late epiblast layer of
postimplantation mouse embryos (Brons
et al., 2007; Tesar et al., 2007). These
cell lines are known as epiblast stem cells
(EpiSCs). Although the growth factor re-
quirements for mouse ESCs and EpiSCs
are different, both cell types express plu-
ripotency markers such as Oct4, Sox2,
and Nanog. Given the current findings of
Xu et al., it will be of interest to investigate
if the TGFb/activin/Smad2/3 pathway
regulates Nanog and other pluripotency
genes in EpiSCs (Figure 1C). If so, EpiSCs
will be revealed to utilize the same molec-
ular pathway as human ESCs to mediate
self-renewal.
The binding sites of Oct4 in human
ESCs, mouse ESCs, and EpiSCs have
been profiled by chromatin immunopre-
cipitation coupled to microarray analysis
(Tesar et al., 2007). While limited overlap
of Oct4 targets was observed between
mouse and human ESCs, mouse EpiSCs
share more similar binding profiles with
human ESCs. This finding raises the pos-
sibility that specific growth factor-in-
duced signaling pathways may modulate
the repertoire of binding sites used in dif-
ferent pluripotent cells. Hence, the utiliza-Elsevier Inc.tion of distinct signal cascades during the
maintenance of human and mouse plurip-
otent cells provides an interesting para-
digm that demonstrates the impact of
extrinsically mediated transcription factor
activation on the intrinsic pluripotent cell
gene and transcription factor network.
Comparative studies using pluripotent
stem cells from different sources and in
different growth conditions should yield
interesting insights into the universality
of the transcriptional regulatory networks
that mediate pluripotency. Such lessons
could then be applied to efforts designed
to induce pluripotency in somatic cells
and also regulate their subsequent di-
rected differentiation to specific desired
lineages.
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